Henry Schein
(Nasdaq: HSIC)
announced today that it completed the acquisition of substantially all the assets of Acentus.
Tampa, Florida-based Acentus, a national medical supplier, specializes in the delivery of continuous glucose monitors (CGMs). The company reports annual revenue of approximately $35 million. Melville, New York-based Henry Schein announced its agreement to acquire the company in November 2024.
Henry Schein expects a neutral impact on its 2025 non-GAAP earnings per share, with an accretive impact thereafter. The company declined to disclose financial terms. As a result of the deal, Acentus founders Brett Carroll, Todd Cianfrocca, Greg Duvall, and Julio Valdivia will join the company and bring their expertise and experience in the product category and the health care industry.
While Acentus specializes in CGMs, the company’s website also lists urological catheters, wound care, incontinence, medical nutrition, ostomy and compression stockings among its offerings.
The company said the acquisition reinforces its strategic commitment to the homecare medical supplies market. It expects this deal to bring its homecare medical products platform revenue to more than $350 million annually.
“Henry Schein continues to expand upon our national homecare solutions platform to effectively address the evolving needs of our customers, which includes clinics, physician practices, health systems, and patients receiving care at home,” said Stanley M. Bergman, chair and CEO of Henry Schein. “The acquisition of Acentus represents an important step towards strengthening our position within the home medical supply market. By directly delivering CGM products to patients’ homes, we are enhancing our ability to serve our valued customers and drive growth.”
